Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this Phase II trial will be to define the activity of a VEGF inhibitor
bevacizumab, HER1/HER2 inhibitor pertuzumab, and sandostatin for patients with
advanced neuroendocrine cancers. In particular, the efficacy of bevacizumab and
pertuzumab treatment is of great interest. The primary endpoint of this trial will be
response rate. Toxicity and progression-free survival will be obtained and evaluated.